Synapse - Mark Geyer

Search Within

Mark Blaine Geyer

Results (91)

Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax

Journal Article

Valtis, Y. K.; Nemirovsky, D.; Derkach, A.; Sharan, S.; Kabel, C.; Ortiz, R.; Thompson, M. C.; Roeker, L. E.; Geyer, M. B.
Blood Advances (2024)

Fulltext@MSK | Save

Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile

Journal Article

Shouval, R.; Goldman, A.; Flynn, J. R.; El-Moghraby, A.; Rehman, M.; Devlin, S. M.; Corona, M.; Landego, I.; Lin, R. J.; Scordo, M.; more...
British Journal of Haematology (2024)

Fulltext@MSK | Save

Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings

Research Letter

Ceyhan-Birsoy, O.; Fiala, E.; Rana, S.; Sheehan, M.; Kennedy, J.; Yelskaya, Z.; Rai, V.; Li, Y.; Yang, C.; Wong, D.; more...
Haematologica (2024)

Fulltext@MSK | Save

Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings

Meeting Abstract

Valtis, Y.; Nemirovsky, D.; Derkach, A.; Roeker, L. E.; Sharan, S.; Kabel, C.; Ortiz, R.; Geyer, M. B.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Acute febrile neutrophilic dermatosis (sweet syndrome) in acute myeloid leukemia patients: A 28-year institutional experience

Journal Article

Cowen, E. A.; Barrios, D. M.; Pulitzer, M. P.; Moy, A. P.; Dusza, S. W.; De Wolf, S.; Geyer, M. B.; Markova, A.
Acta Haematologica (2024)

Fulltext@MSK | Save

Multilineage involvement in KMT2A-rearranged B acute lymphoblastic leukaemia: Cell-of-origin, biology, and clinical implications

Journal Article

Aypar, U.; Dilip, D.; Gadde, R.; Londono, D. M.; Liu, Y.; Gao, Q.; Geyer, M. B.; Derkach, A.; Zhang, Y.; Glass, J. L.; more...
Histopathology (2024)

Fulltext@MSK | Save

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save

Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: Results of a phase I trial

Meeting Abstract

Valtis, Y. K.; Geyer, M. B.; Torres, M.; Grogan, M.; Shukla, M.; Stein, E. M.; Park, J. H.
Blood (2023)

Fulltext@MSK | Save

Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions

Meeting Abstract

Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
Blood (2023)

Fulltext@MSK | Save

Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Primary endpoint results from the BLISSPHALL study

Meeting Abstract

Geyer, M. B.; Mascarenhas, J.; Smith, M.; Pascual, S.; Shah, A.; Silvestrone, M. R.; Czaplinska, T.; Johnson, K.; Thompson, M. C.; Park, J. H.
Blood (2023)

Fulltext@MSK | Save